Gottsegen Gy Hungarian Institute Of Cardiolog, Bonyhad (Hungary)
0
follower
53
more
presentations
in this session
Differences between randomized controlled clinical trials and real-world atrial fibrillation patients treated with oral anticoagulants - do we treat the same patients? Results from the CRAFT study
Which factors influence the choice of a non-vitamin K oral anticoagulant over warfarin for stroke prevention among atrial fibrillation patients? Insights from the prospective SPRINT-AF registry.
Real-world effectiveness of stroke prevention in patients with non-valvular atrial fibrillation treated with rivaroxaban vs. phenprocoumon in germany - insights from the reload study
Increased thromboprophylactic treatment of patients with atrial fibrillation after the introduction of NOACs - an analysis of sex and gender differences
Comparison of stroke- and bleed-related healthcare resource utilization (HCRU) among patients with non-valvular atrial fibrillation (NVAF), newly treated with oral anti-coagulants (OACs)
Speaker:
Doctor J. Franchino-Elder (Ridgefield, US)